(Total Views: 221)
Posted On: 09/16/2020 2:17:53 PM
Post# of 188
NetworkNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Strategic Scientific Advisory Board Appointment
DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics market, today announced that Eric Milledge has joined DarioHealth as chairman of the company’s newly-established Scientific Advisory Board (“SAB”). Milledge has dedicated his entire career to the field of health care, with a focus on pharmaceuticals and medical devices, and spent 34 years at Johnson & Johnson, building a vast network of relationships across the health-care landscape. “We are very pleased that Eric is spearheading our effort to assemble a world-class SAB,” said Dario’s CEO Erez Raphael in the press release. “He brings significant experience and knowledge relevant to our industry, and a vast network of thought leaders across the diabetes treatment landscape. We believe Eric can help take our technology to the next level by attracting scientific and strategic business partners who will strengthen our platform and ultimately our reputation as a pioneer and leader in digital therapeutics. We believe that our leadership position will improve our ability to execute within the B2B2C channel, winning new accounts and further penetrating the significant opportunity that already exists within our current customer base.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics market, today announced that Eric Milledge has joined DarioHealth as chairman of the company’s newly-established Scientific Advisory Board (“SAB”). Milledge has dedicated his entire career to the field of health care, with a focus on pharmaceuticals and medical devices, and spent 34 years at Johnson & Johnson, building a vast network of relationships across the health-care landscape. “We are very pleased that Eric is spearheading our effort to assemble a world-class SAB,” said Dario’s CEO Erez Raphael in the press release. “He brings significant experience and knowledge relevant to our industry, and a vast network of thought leaders across the diabetes treatment landscape. We believe Eric can help take our technology to the next level by attracting scientific and strategic business partners who will strengthen our platform and ultimately our reputation as a pioneer and leader in digital therapeutics. We believe that our leadership position will improve our ability to execute within the B2B2C channel, winning new accounts and further penetrating the significant opportunity that already exists within our current customer base.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
